Should Cost of Therapy Be Considered in CV Guidelines?

New cardio drugs, such as PCSK9 inhibitors and the angiotensin receptor neprilysin inhibitor, are expensive. Dr O ' Donoghue asks whether that should affect guideline recommendations.

Source: Medscape Cardiology Podcast - March 6, 2017 Category: Cardiology Authors: Medscape Source Type: podcasts